NCT00742131 2017-07-31
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
Clinical Trials
4 trialsNCT00743067 2017-07-26
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00920192 2017-07-18
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00742261 2017-07-07
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed